Carl Gordon Headshot
Are you Carl Gordon?
Claim Carl's Profile

Carl Gordon    

Founding General Partner, OrbiMed

Carl Gordon returns to the Midas List for his second appearance thanks to a robust market for biotech buyouts and IPOs. Gordon invested in Seragon Pharmaceuticals' Series A in 2013 and a year later Swiss drugmaker Roche Group said it would acquire the breast cancer drugmaker for up to $1.7 billion. His other big deals of late include cancer drugmaker Aragon Pharmaceuticals (acquired by Johnson & Johnson for up to $1 billion in 2013), Acceleron Pharma (IPO 2013), hepatitis C drugmaker Inhibitex (acquired by Bristol-Myers Squibb for $2.5 billion in 2012) and in-demand antibody developer Adimab. Gordon, a Ph.D. in molecular biology from MIT and a chartered financial analyst, helped start OrbiMed's venture business in 2000. OrbiMed has since grown into the world's largest life sciences-dedicated investment firm.

Click Here to register and get pricing on booking Carl Gordon for your next event!

Request Pricing & Booking Info

Speakerpedia has booked over a thousand events in the past 5 years. Contact Carl Gordon's Booking Agent to get availability & pricing.

Videos


No videos yet.

Get notified of new talks and events.

Follow

Related Speakers View all


More like Carl